本研究旨在确定I B期非小细胞肺癌（NSCLC）的长期预后因素。回顾性评估了2008年4月至2013年12月之间根据TNM第8版诊断的I B期NSCLC的手术切除患者的预后和可能风险因素。经过筛选，共有349名患者符合研究条件，其中80人（22.9％）接受了手术后辅助化疗（ACT）。术后中位随访时间为123.3个月，10年总体生存率（OS）为69.6％，10年无复发生存率（RFS）为62.8％。将该队列中的患者划分为三组（T1伴有浸润性胸膜，T2a无浸润性胸膜，T2a伴有浸润性胸膜），发现组间OS和RFS没有显著差异。此外，生存分析表明无玻璃样阴影（GGO）成分与恶劣的长期OS和RFS有关。在实质性结节亚组中，年龄大于65岁（风险比[HR] 1.987；95％置信区间[CI] 1.312-3.010；p = 0.001）和ACT（HR 0.392；95％ CI 0.225-0.684；p <0.001）是OS的独立预后因素，而淋巴血管侵犯（HR 1.792；95％ CI 0.995-3.227；p = 0.052）应被视为RFS的独立不良预后因素。作为上分期因素，浸润性胸膜对于我们队列中的I B期患者的预后没有进一步分层。玻璃样阴影组分对I B期NSCLC的有利预后产生了显着影响。© 2023年。外科肿瘤学学会。

This study aimed to determine the prognostic factors for the long-term outcome of stage IB non-small cell lung cancer (NSCLC).Surgically resected patients with stage IB NSCLC diagnosed (based on TNM 8th edition) between April 2008 and December 2013 were retrospectively reviewed. The prognosis and possible risk factors among the stage IB NSCLC patients were evaluated.Of the 349 patients identified for the study, 80 (22.9%) received post-surgery adjuvant chemotherapy (ACT). The median follow-up time after surgery was 123.3 months. The 10-year overall survival (OS) rate was 69.6%, and the 10-year recurrence-free survival (RFS) rate was 62.8%. The patients in this cohort were divided into three groups (T1 with visceral pleural invasion [VPI], T2a without VPI, and T2a with VPI), and no significant differences in OS or RFS were found among the groups. Furthermore, survival analysis indicated that the absence of ground-glass opacity (GGO) components portends an adverse long-term OS and RFS. In a subgroup of patients with solid nodules, age older than 65 years (hazard ratio [HR] 1.987; 95% confidence interval [CI] 1.312-3.010; p = 0.001) and ACT (HR 0.392; 95% CI 0.225-0.684; p < 0.001) were independent prognostic factors for OS, whereas lymphovascular invasion (HR 1.792; 95% CI 0.995-3.227; p = 0.052) should be considered as an independent unfavorable prognostic factor for RFS.As an upstaging factor, VPI did not further stratify prognosis for the stage IB patients in our cohort. The presence of GGO components had a notable impact on a favorable prognosis in stage IB NSCLCs.© 2023. Society of Surgical Oncology.